Influence of non-toxic doses of bevacizumab and ranibizumab on endothelial functions and inhibition of angiogenesis

Current Eye Research

Volumn 35, Issue 9, 2010, Pages 835-841

  Barzelay, Aya ^a   Lowenstein, Anat ^b   George, Jacob ^a   Barak, Adiel ^b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Age related macular degeneration; Angiogenesis; Anti angiogenic therapy; Choroidal neovascularization; Retina

Indexed keywords

BEVACIZUMAB; FIBRONECTIN; LIPOCORTIN 5; MATRIGEL; RANIBIZUMAB;

ANGIOGENESIS; ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL CULTURE; CELL FUNCTION; CELL PROLIFERATION; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; ENDOTHELIUM CELL; HEART MUSCLE CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA; STAINING;

EID: 77956152299     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2010.489727     Document Type: Article

References (32)

1. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specifc for vas cular endothelial cells. Biochem Biophys Res Commun. 1989;161:851-858.
2. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431.
3. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: Subgroup analysis of frst-year ANCHOR results. Am J Ophthalmol. 2007;144:850-857.
4. Kramer I, Lipp HP. Bevacizumab, a humanized anti-angio-genic monoclonal antibody for the treatment of colorectal cancer. J Clin Pharm Ther. 2007;32:1-14.
5. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal Bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-372, e365.
6. Moreno SF, Paloma JB. Therapeutic anti-VEGF in age-related macular degeneration: Ranibizumab and Bevacizumab controversy. Br J Ophthalmol. 2008;92:866-867.
7. Klettner A, Roider J. Comparison of Bevacizumab, ranibi-zumab, and pegaptanib in vitro: Effciency and possible additional pathways. Invest Ophthalmol Vis Sci. 2008;49:4523-4527.
8. Spitzer MS, Wallenfels-Thilo B, Sierra A, et al. Antiprolifera-tive and cytotoxic properties of Bevacizumab on different ocular cells. Br J Ophthalmol. 2006;90:1316-1321.
9. Garlanda C, Parravicini C, Sironi M, et al. Progressive growth in immunodefcient mice and host cell recruitment by mouse endothelial cells transformed by polyoma middle-sized T antigen: Implications for the pathogenesis of opportunistic vascular tumors. Proc Natl Acad Sci\USA. 1994;91:7291-7295.
10. Barzelay A, Ben-Shoshan J, Entin-Meer M, Maysel-Auslender S, Afek A, Barshack I, Keren G, George J. A potential role for islet-1 in post-natal angiogenesis and vasculogenesis. Thromb Haemostasis. 2010;103(1):188-197. Epub 2009 Oct 26.
11. Ben-Shoshan J, Maysel-Auslender S, Luboshits G, et al. Hypoxia-inducible factor-1alpha and-2alpha additively promote endothelial vasculogenic properties. J Vasc Res. 2009;46:299-310.
12. Ben-Shoshan J, Schwartz S, Luboshits G, et al. Constitutive expression of HIF-1alpha and HIF-2alpha in bone marrow stromal cells differentially promotes their proangiogenic properties. Stem Cells. 2008;26:2634-2643.
13. Kim BS, Mooney DJ. Engineering smooth muscle tissue with a predefned structure. J Biomed Mater Res. 1998;41:322-332.
14. Bouhadir KH, Mooney DJ. In vitro and in vivo models for the reconstruction of intercellular signaling. Ann N Y Acad Sci. 1998;842:188-194.
15. Gien J, Seedorf GJ, Balasubramaniam V, et al. Intrauterine pulmonary hypertension impairs angiogenesis in vitro: Role of vascular endothelial growth factor nitric oxide signaling. Am J Respir Crit Care Med. 2007;176:1146-1153.
16. Bischoff J. Cell Adhesion and Angiogenesis. J Clin Invest. 1997;99:373-376.
17. Vacca A, Iurlaro M, Ribatti D, et al. (1999) Antiangiogen-esis is produced by nontoxic doses of vinblastine. Blood. 1999;94:4143-4155.
18. Vailhe B, Vittet D, Feige JJ. In vitro models of vasculogenesis and angiogenesis. Lab Invest. 2001;81:439-452.
19. Friedlander M, Brooks PC, Shaffer RW, et al. (1995) Defni-tion of two angiogenic pathways by distinct alpha v integ-rins. Science. 1995;270:1500-1502.
20. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564-572.
21. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9:653-660.
22. Zacharek A, Chen J, Cui X, et al. Angiopoietin1/Tie2 and VEGF/Flk1 induced by MSC treatment amplifes angiogen-esis and vascular stabilization after stroke. J Cereb Blood Flow Metab. 2007;27:1684-1691.
23. Millauer B, Wizigmann-Voos S, Schnurch H, et al. High affnity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angio-genesis. Cell. 1993;72:835-846.
24. Heiduschka P, Fietz H, Hofmeister S, et al. Penetration of Bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci. 2007;48: 2814-2823.
25. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of Bevacizumab (Avastin). Retina. 2006;26:262-269.
26. Zhao B, Ma A, Cai J, et al. VEGF-A regulates the expression of VEGF-C in human retinal pigment epithelial cells. Br J Ophthalmol. 2006;90:1052-1059.
27. Kurzen H, Schmitt S, Naher H, et al. Inhibition of angiogen-esis by non-toxic doses of temozolomide. Anticancer Drugs. 2003;14:515-522.
28. Ferrara N, Damico L, Shams N, et al. Development of ranibi-zumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26:859-870.
29. Costa RCA, Rocha A, Pirraco A, et al. Bevacizumab and Ranibizumab on microvascular endothelial cells: A comparative study. J Cell Biochem. 2009;108:1410-1417.
30. Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol. 1999;27:536-544.
31. Daniel F Martin, The Cleveland Clinic, Stuart L Fine, MD, Study Vice-Chair, University of Pennsylvania, Maureen G Maguire, PhD, Director of Coordinating Center, University of Pennsylvania, Glenn Jaffe, MD, Director of OCT Reading Center, Duke University, Juan E Grunwald, MD, Principal Investigator of Photography Reading Center, Universisty of Pennsylvania. Comparison of Age-related Macular De generation Treatments Trials: Lucentis-Avastin Trial. Retrieved March 23, 2010, from http://clinicaltrials.gov/ct2/show/NCT00593450.
32. Daniel F Martin, The Cleveland Clinic, Stuart L Fine, MD, Study Vice-Chair, University of Pennsylvania, Maureen G Maguire, PhD, Director of Coordinating Center, University of Pennsylvania, Glenn Jaffe, MD, Director of OCT Reading Center, Duke University, Juan E Grunwald, MD, Principal Investigator of Photography Reading Center, Universisty of Pennsylvania. Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial. Retrieved March 1, 2010, from http://clinicaltrials.gov/ct2/results term=ranibizumab+Bevacizumab &pg=2.